Adage Capital Partners
ACHN

Adage Capital Partners’s Achillion Pharmaceuticals ACHN Stock Holding History

Adage Capital Partners’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-800,700
Closed -$5.53M – 757
2015
Q3 		$5.53M Sell
800,700
-2,217,730
-73% -$18.1M 0.02% 606
2015
Q2 		$26.7M Buy
3,018,430
+175,000
+6% +$1.66M 0.07% 350
2015
Q1 		$28M Buy
2,843,430
+1,200,000
+73% +$15M 0.07% 344
2014
Q4 		$20.1M Buy
+1,643,430
New +$20.1M 0.05% 407
2014
Q2 		– Sell
-870,009
Closed -$2.86M – 761
2014
Q1 		$2.86M Buy
+870,009
New +$3.04M 0.01% 630
2013
Q4 		– Sell
-628,267
Closed -$1.9M – 738
2013
Q3 		$1.9M Sell
628,267
-787,200
-56% -$5.4M 0.01% 647
2013
Q2 		$11.6M Buy
+1,415,467
New +$10.8M 0.04% 467

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Adage Capital Partners's ACHN Position: Q4 2015 in Review

Adage Capital Partners sold out of Achillion Pharmaceuticals (ACHN) in Q4 2015, closing a stake of 800,700 shares — an estimated $5.53M sold.

Adage Capital Partners first reported a position in ACHN in Q2 2013 and held it in 7 quarters. The position peaked at $28M in Q1 2015. 152 funds tracked by Wall St. Rank hold ACHN as of Q4 2015.

  • Adage Capital Partners reported no remaining Achillion Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Adage Capital Partners sold 800,700 Achillion Pharmaceuticals shares in Q4 2015, an estimated $5.53M.
  • Adage Capital Partners first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 7 quarters.
  • Adage Capital Partners's Achillion Pharmaceuticals position peaked at $28M in Q1 2015.
  • 152 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2015.

Based on Adage Capital Partners's 13F filing for Q4 2015, filed 16 Feb 2016.